Kogenate treatment of previously untreated patients (PUPs) with hemophilia A: Update of safety, efficacy, and inhibitor development after seven study years.

被引：0
|
作者：
Lusher, J
Arkin, S
Abildgaard, CF
Hurst, D
机构：
[1] MT SINAI SCH MED,NEW YORK,NY
[2] WAYNE STATE UNIV,DETROIT,MI
[3] BAYER CORP,BERKELEY,CA
[4] UNIV CALIF DAVIS,SACRAMENTO,CA 95817
来源：
BLOOD | 1996年 / 88卷 / 10期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：1755 / 1755
页数：1
相关论文
共 50 条
  • [21] Final results of the PUPs B-LONG study: evaluating safety and efficacy of rFIXFc in previously untreated patients with hemophilia B
    Nolan, Beatrice
    Klukowska, Anna
    Shapiro, Amy
    Rauch, Antoine
    Recht, Michael
    Ragni, Margaret
    Curtin, Julie
    Gunawardena, Sriya
    Mukhopadhyay, Sutirtha
    Jayawardene, Deepthi
    Winding, Bent
    Fischer, Kathelijn
    Liesner, Raina
    BLOOD ADVANCES, 2021, 5 (13) : 2732 - 2739
  • [22] SAFETY, EFFICACY AND INHIBITOR RISK OF RECOMBINANT FACTOR-VIII (RECOMBINATE(R)) IN A COHORT OF PREVIOUSLY UNTREATED PATIENTS (PUPS) WITH SEVERE HEMOPHILIA-A
    BRAY, GL
    COURTER, S
    LYNES, M
    LEE, M
    GOMPERTS, E
    THROMBOSIS AND HAEMOSTASIS, 1993, 69 (06) : 1205 - 1205
  • [23] Inhibitor development in previously untreated patients (PUPs) with hemophilia A and B: A prospective 23-year-follow-up
    Ettingshausen, CE
    Zyschka, A
    Oldenburg, J
    Saguer, IM
    Ehrenforth, S
    Kreuz, W
    Goethe, JW
    THROMBOSIS AND HAEMOSTASIS, 1999, : 410 - 410
  • [24] RECOMBINANT FACTOR-VIII FOR THE TREATMENT OF PREVIOUSLY UNTREATED PATIENTS WITH HEMOPHILIA-A - SAFETY, EFFICACY, AND DEVELOPMENT OF INHIBITORS
    LUSHER, JM
    ARKIN, S
    ABILDGAARD, CF
    SCHWARTZ, RS
    NEW ENGLAND JOURNAL OF MEDICINE, 1993, 328 (07): : 453 - 459
  • [25] EFFICACY AND SAFETY OF PROPHYLAXIS IN PREVIOUSLY UNTREATED PATIENTS WITH SEVERE HEMOPHILIA A IN IRAN
    Karimi, M.
    Eshghi, P.
    Haghpanah, S.
    Zahedi, Z.
    Habibpanah, B.
    HAEMATOLOGICA, 2015, 100 : 409 - 409
  • [26] Inhibitor incidence in previously untreated patients (PUPs) with severe hemophilia A receiving recombinant factor (rFVIII)
    Rothschild, C
    Laurian, Y
    Satre, EP
    BorelDerlon, A
    Chambost, H
    Moreau, P
    Goudemand, J
    Parquet, A
    Vicariot, M
    Beurrier, P
    Claeyssens, S
    Durin, A
    Faradji, A
    Fressinaud, E
    Gaillard, S
    Guerin, V
    Guerois, C
    Pernod, G
    Peynet, J
    Pouzol, P
    Schved, JF
    Gazengel, C
    THROMBOSIS AND HAEMOSTASIS, 1997, : P2654 - P2654
  • [27] CD-4 COUNTS IN HIV-NEGATIVE PREVIOUSLY UNTREATED PATIENTS (PUPS) WITH HEMOPHILIA-A RECEIVING RECOMBINANT FVIII (KOGENATE)
    WARRIER, I
    ARKIN, S
    ABILDGAARD, C
    TENGBOM, L
    ZIMMERMANN, R
    HURST, D
    BLOOD, 1993, 82 (10) : A601 - A601
  • [28] Safety, efficacy and inhibitor development in previously untreated patients (PUPs) treated exclusively with recombinant B domain deleted recombinant FVIII (BDDrFVIII).
    Lusher, JM
    Gringeri, A
    Hann, I
    Rodriguez, D
    BLOOD, 1999, 94 (10) : 234A - 235A
  • [29] Treatment-related risk factors of inhibitor development in previously untreated patients with hemophilia A: the CANAL cohort study
    Gouw, Samantha C.
    van der Bom, Johanna G.
    van den Berg, H. Marijke
    BLOOD, 2007, 109 (11) : 4648 - 4654
  • [30] Treatment characteristics and the risk of inhibitor development: a multicenter cohort study among previously untreated patients with severe hemophilia A
    Gouw, S. C.
    van den Berg, H. M.
    le Cessie, S.
    van der Bom, J. G.
    JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2007, 5 (07) : 1383 - 1390
12345